跳至主要内容
临床试验/NL-OMON55733
NL-OMON55733已完成4 期

The effects of sex hormone administration on marrow and visceral adiposity - SHAMVA

Vrije Universiteit Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Diagnosed with gender dysphoria according to DSM V (transmen or
  • transwomen)
  • - Age between 18 and 50 years
  • - Transmen need to be premenopausal
  • - Starting cross-sex hormone treatment

排除标准

  • - Previous use of cross-sex hormones
  • - Use of hormonal contraceptives (exception for Mirena sipral)
  • - Contraindications to MRI scanning as determined by the standard AMC checklist
  • - Use of bone-modifying or adipose tissue-modifying drugs, current or in history
  • - Bisphosphonates (alendronic acid, clodronic acid, ibandronic acid, pamidronic
  • acid, risedronic acid, zoledronic acid, etidronate)
  • - Estrogen receptor modulators (raloxifene, bazedoxifene)
  • - Calcium regulating agents (e.g. denosumab, calcitonin, teriparatide,
  • strontium ranelate, cinacalcet, etelcalcetine)
  • - Corticosteroids
  • - Bone or bone marrow diseases, current or in history
  • - Metabolic (osteroporosis, osteomalacia, dystosis, osteodystrophia, Pagets
  • disease, osteogenesis imperfecta)
  • - Malignancy (primary, metastatic)
  • - Infectious (osteomyelitis, periostitis), Mechanic (lumbal vertebral
  • fracture), Bone marrow diseases (leukemia, myelodysplastic syndrome,
  • myeloproliferative disorders)
  • - Platelet count <120*10^9/l
  • - History of non-traumatic major bleeding
  • - Known bleeding diathesis
  • - Conditions which require antiplatelet therapy
  • - Usage of antiplatelet therapy
  • - Chronic usage of medication known to influence platelet function (e.g.
  • DOAC*s, NSAIDs, warfarin)

研究者

相似试验